# A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

> **NCT04024696** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Xynomic Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Abexinostat

## Key facts

- **NCT ID:** NCT04024696
- **Lead sponsor:** Xynomic Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-08
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024696, "A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04024696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*